Dr. Reddy’s Laboratories Ltd., of Hyderabad, India, said the FDA approved its drug-device product to treat acute migraines, with or without aura, for adults with unmanaged symptoms, who have been receiving other treatments. Zembrace Symtouch (sumatriptan succinate), a prefilled, ready-to-use, single-dose disposable autoinjector. is not recommended for those younger than 18. The product will be marketed in the U.S. by Promius Pharma, which is wholly owned by Dr. Reddy’s.